About the Company
We do not have any company description for Invivyd, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Invivyd, Inc.
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
The securities described above were offered by Invivyd pursuant to a shelf registration statement on Form S-3 (File No. 333-267643) filed with the U.S. Securities and Exchange Commission (SEC) on ...
COVID-19 “Vaccine Alternative” Injection Could Be On Fast-Track To Approval From FDA
Pharma company Invivyd, Inc. just announced it is working with the US Food and Drug Administration (FDA) on a pathway to ...
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain ...
Demystifying Invivyd: Insights From 5 Analyst Reviews
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $5.0, with a high estimate of $9.00 and a low estimate of $3.00. This current average has ...
Invivyd Announces Proposed Public Offering of Common Stock
Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an ...
Invivyd, Inc. to Host Conference Call on May 15, 2025, to ... - Nasdaq
Invivyd, Inc., a biopharmaceutical company focused on developing treatments for serious viral infectious diseases, has announced a conference call on May 15, 2025, at 8:30 a.m. ET to discuss its ...
Invivyd, Inc. Secures $30 Million Term Loan Facility from Silicon ...
Invivyd, Inc. Secures $30 Million Term Loan Facility from Silicon Valley Bank to Advance Viral Infectious Disease Pipeline April 21, 2025 — 07:14 am EDT Written by None for Quiver Quantitative -> ...
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.4 per share a year ago. These figures are ...
Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus")
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG ...
Invivyd, Inc. (IVVD) Q3 2023 Earnings Call Transcript
Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ETCorporate ParticipantsScott Young - SVP, Investor Relations and ...
Invivyd, Inc. (IVVD) CEO David Hering on Q3 2022 Results - Earnings ...
Invivyd, Inc. (NASDAQ: IVVD) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Kyra Faircloth - VP, Government Affairs, Advocacy and Corporate Communication ...
Similar Companies
Loading the latest forecasts...